Combretastatin A-4 and Its Analogues as Antineoplastic Agents

Dzierzbicka, K.; Kołodziejczyk, A.

Artykuł - szczegóły

Tytuł artykułu

Combretastatin A-4 and Its Analogues as Antineoplastic Agents

Autorzy

Dzierzbicka K. , Kołodziejczyk A.

Identyfikatory

Warianty tytułu

Języki publikacji

Abstrakty

Combretastatin A-4 is a potent antineoplastic and antiangiogenesis natural substance isolated from the South African treeCombretum caffrum. This article concerns synthesis and biological activity of combretastatin A-4 and its analogues which are considered as prodrugs.

Słowa kluczowe

combretastatin A-4 angiogenesis inhibitors synthesis biological activity antimitotic agents antineoplastic agent

Wydawca

Polskie Towarzystwo Chemiczne

Czasopismo

Polish Journal of Chemistry

Rocznik

2004

Tom

Vol. 78 / nr 3

Strony

323--341

Opis fizyczny

Bibliogr. 64 poz., rys.

Twórcy

autor

Dzierzbicka K.

Department of Organic Chemistry, Gdańsk University of Technology, 11/12 G. Narutowicza Street, 80-952 Gdańsk, Poland

autor

Kołodziejczyk A.

Department of Organic Chemistry, Gdańsk University of Technology, 11/12 G. Narutowicza Street, 80-952 Gdańsk, Poland

Bibliografia

1. Folkman J„ N. Engl. J. Med., 285, 1182 (1971).
2. O’Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R. and Folkamn J., Cell, 88, 277 (1997).
3. Harris A.L., Lancet, 351, 1598 (1998).
4. Gourley M. and Williamson J.S., Curr. Pharmacol Design, 6,417 (2000).
5. Aiello L.P., Nature Med., 6, 379 (2000).
6. Liekens S., De Clercq E. and Neyts J., Biochemical Pharmacology, 61, 253 (2001).
7. Opolski A. and Wietrzyk J., Post. Hig. Med. Dosw., 55, 369 (2001).
8. Rowinsky E.K., Donehower R.C., In Cancer, Principle and Practice of Oncology, 5 th ed.; DeVita V.T., Jr, Heilman S., Rosenberg S.A., eds.: Lippincott-Raven: Philadelphia, pp. 467-483 (1997).
9.Iwasaki S., J. Pharmacol. Soc. Jpn., 118, 111 (1998).
10. Li Q., Sham H.L., Rosenberg S.H., Antimitotic Agents. In Annual Reports in Medicinal Chemistry, Doherty A.M., Ed.; Academic Press: San Diego, Vol. 34, pp. 139-148 (1999).
11. Shi Q., Chen K., Morris-Natschke S.L. and Lee K.H., Curr. Pharm. Des., 4, 219 (1998).
12. Jordan A., Hadfield J.A., Laurence N.J. and McGown A.T., Med. Chem. Rev., 18, 259 (1998).
13. Pettit G.R., Singh S.B., Niven M.L., Hamel E. and Schmidt J.M.,/ of Natural Products, 50,119 (1987).
14. Pettit G.R. and Singh S.B., Can. J. Chem., 65, 2390 (1987).
15. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S. and Garcia-Kendall D., Experientia, 45,209 (1989).
16. Pettit G.R., Singh S.B. and Cragg G.M., J Org. Chem., 50, 3404(1985).
17. Singh S.B. and Pettit G.R., J. Org. Chem., 54, 4105 (1989).
18. Pettit G.R., Singh S.B., Boyd M.R., Hamel E., Pettit R.K., Schmidt J.M. and Hogan F,,J. Med. Chem., 38, 1666(1995).
19. Ohsumi K., Nakagawa R., Fukuda Y., Hatanaka T., Morinaga Y., Nihei Y., Ohishi K., Suga Y., Akiyama Y. and Tsuji l.,J. Med. Chem., 41, 3022 (1998).
20. Brown R.T., Fox B.W., Hadfield J.A., McGown A.T., Mayalarp S.P., Pettit G.R. and Woods J.A., J. Chem. Soc. Perkin Trans. 1, 5, 577 (1995).
21. Woods J.A., Hadfield J.A., Pettit G.R., Fox B.W. and McGown A.T., Br. J. Cancer, 71, 705 (1995).
22. Bedford S.B., Quarterman C.P., Rathbone D.L., Slack J.A., Griffin B.J. and Stevens M.F.G., Bioorg. Med. Chem. Lett., 6, 157 (1996).
23. Pettit G.R., Temple C., Jr, Narayanan V.L., Varma R., Simpson M.J., Boyd M.R., Rener G.A. and Bansal N., Anti-Cancer Drug Design, 10,299 (1995).
24. Chaplin D.J., Pettit G.R. and Hill S.A., Anticancer Res., 19, 189 (1999).
25. Dziba J.M., Marcinek R., Venkataraman G., Robinson J.A. and Ain K.B., Thyroid, 12, 1063 (2002).
26. Hua J., Sheng Y., Pinney K.G., Gamer C.M., Kane R.R., Prezioso J.A., Pettit G.R, Chaplin D.J. and Edvardsen K., Anticancer Res., 23, 1433 (2003).
27. Pettit G.R. and Rhodes M.R., Anti-Cancer Drug Design, 13, 183 (1998).
28. Kerekes P., Sharma P.N., Brossi A., Chignell C.F. and Quinn F.R, J. Med. Chem., 28, 1204 (1985).
29. Dumont R, Brossi A., Chignell C.R, Quinn RR. and Suffness M.A., J. Med. Chem., 30, 732 (1987).
30. Hamel E., Ho H.H., Kang G.J. and Lin C.M., Biochem. Pharmacol., 37, 2445 (1988).
31. Muzaffar A., Brossi A., Lin C.M. and Hamel E., J. Med. Chem., 33, 567 (1990).
32. Zavala R, Guenard D., Robin J.P. and Brown E,,J. Med. Chem., 23, 546 (1980).
33. Van der Eycken J., Bosnians J.P., Van Haver D., Vandewalle M., Hulkenberg A.,Veerman W. and Nieuwenhuizen R., Tetrahedron Lett., 30, 3873 (1989).
34. Klein L.L., Yeung C.M., Chu D.T., McDonald E.J., Clementy J.J. and Plattner J.J., J. Med. Chem., 34, 984 (1991).
35. Wang R.W.J., Rebhun L.I. and Kupchan S.M., Cancer Res., 37, 3071 (1977).
36. Tomioka K., Ishiguro T., Mizuguchi H., Komeshima N., Koga K., Tsukagoshi S., Tsuruo T., Tashiro T., Tanida S. and Kishi T„ J. Med. Chem., 34, 54 (1991).
37. Itoh Y., Brossi A., Hamel E. and Lin C.M., Helv. Chim. Acta, 71, 1199 (1988).
38. Batra J.K, Jurd L. and Hamel E., Mol. Pharmacol, 27, 94 (1985).
39. Batra J.K., Kang G.J., Jurd L. and Hamel E., Biochem. Pharmacol., 37,2595 (1988).
40. Edwards M.L., Stemerick D.M. and Sunkara P.S., J. Med. Chem., 33, 1948 (1990).
41. Lin C.M., Singh S.B., Chu P.S., Dempcy R.O., Schmidt J.M., Pettit GR. and Hamel E., Mol. Pharmacol., 34, 200(1988).
42. Cushman M., Nagarathnam D., Gopal D., Chakraborti A.K., Lin Ch.M. and Hamel E., J. Med. Chem., 34, 2579(1991).
43. Cushman M., Nagarathnam D., Gopal D., Hu-Ming He., Lin Ch.M. and Hamel E., J. Med. Chem., 35, 2293(1992).
44. Xia Y., Yang Z.Y., Xia P., Bastow K.R, Tachibana Y., Kuo S.Ch., Hamel E., Hackl T. and Lee K.H., J. Med. Chem., 41, 1155 (1998).
45. Ohsumi K., Hatanaka T., Fujita K., Nakagawa R., Fukuda Y., Niher Y., Suga Y., Morinaga Y., Akiyama Y. and Tsuji T., Bioorg. Med. Chem. Lett., 8, 3153 (1998).
46. Shirai R., Takayama H., Nishikawa A., Koiso Y. and Hashimoto Y., Bioorg. Med. Chem. Lett., 8, 1997 (1998).
47. Medarde M., Ramos A.C., Caballero E., de Clairac R.P.L., Lopez J.L., Gravalos D.G. and Feliciano A.S., Bioorg. Med. Chem. Lett., 9,2303 (1999).
48. Gwaltney S.L., Imade H.M., Barr K.J., Li Q., Gehrke L., Credo R.B., Warner R.B., Lee J.Y., Kovar P., Wang J.,NukkalaM.A., Zielinski N.A., Frost D.,NgS.C. and Sham H.L., Bioorg. Med. Chem. Lett., 11, 871 (2001).
49. Wang L., Woods K.W., Li Q., Barr K.J., McCroskey R.W., Hannick S.M., Gherke L., Credo R.B., Hui Y.H., Marsh K., Warner R., Lee J.Y., Zielinski-Mozng N., Frost D., Rosenberg S.H. and Sham H.L., J. Med. Chem., 45, 1697 (2002).
50. Orsini F., Pelizzoni F., Bellini B. and Miglierini G., Carbohydr. Res., 301, 95 (1997).
51. Lawrence N.J., Ghani F.A., Hepworth L.A., Hadfield J.A., McGown A.T. and Pritchard R.G., Synthesis, 1656(1999).
52. Furstner A. and Nikolakis K., Liebigs Ann. Chem., 2107 (1996).
53. Gaukroger K., Hadfield J.A., Hepworth L. A., Lawrence N.J. and McGown A.T., J. Org. Chem., 66,8135 (2001).
54. Pettit G.R., Lippert J.W., Herald D.L., Hamel E. and Pettit R.K., J. Nat. Prod., 63, 969 (2000).
55. Dark G.G., Hill S. A., Prise V.E., Tozer G.M., Pettit G.R. and Chaplin D.J., Cancer Res., 57,1829 (1997).
56. Lin C.M., Ho H.H., Pettit G.R. and Hamel E., Biochemistry, 28, 6984 (1989).
57. Pettit G.R., Toki B., Herald D.L., Verdier-Pinard P., Boyd M.R. and Hamel E., J Med. Chem.,41, 1688 (1998).
58. Iyer S., Chaplin D. J., Rosenthal D.S., Boulares A.H., Li L.Y. and Smulson M.E., Cancer Res., 58,4510 (1998).
59. DarkG.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R. and Chaplin D.J., Cancer Res., 57,1829.(1997).
60. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R., Dennis M.F. and Chaplin D.J., Cancer Res., 59, 1626 (1999).
61. Dzierzbicka K., Kotodziejczyk A.M., Wysocka-Skrzela B., Mysliwski A. and Sosnowska D., J. Med. Chem., 44, 3606(2001).
62. Sosnowska D., Myiliwski A., Dzierzbicka K. and Kolodziejczyk A., Biotherapy, 10, 161 (1997).
63. Dzierzbicka K. and Kołdziejczyk A.M., J. Med. Chem., 46, 183 (2003).
64. Dzierzbicka K., Trzonkowski P., Sewerynek P. and Myśliwski A., J. Med. Chem., 46, 978 (2003).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-article-BUJ1-0023-0178